#FDA approval

The overall response rate was 61% for patients treated with the bispecific T-cell engager.

Omidubicel led to faster neutrophil recovery following umbilical cord blood transplantation.

Half of patients with this rare skin cancer experienced tumor shrinkage when treated with the new checkpoint inhibitor.

Newly FDA-approved drugs for ovarian, bladder, liver cancer, and more.

This treatment represents a “fairly substantial breakthrough” for patients with HER2-positive advanced colorectal cancer.

The antibody-drug conjugate is now approved for patients with hormone receptor-positive/HER2-negative or triple-negative breast cancer.

The Dana-Farber led ALPINE trial looked at the drug in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Orserdu (elacestrant) is the first treatment for people with ESR1 mutations, which can drive resistance to standard hormone therapy.

Jaypirca (pirtobrutinib) is a highly selective kinase inhibitor that utilizes a novel binding mechanism.

Mosunetuzumab is the first bispecific antibody, a type of immunotherapy, approved to treat non-Hodgkin lymphoma.

Rezlidhia (olutasidenib) is approved as a targeted treatment option for adults whose acute myeloid leukemia carries the IDH1 mutation.

Krazati led to tumor shrinkage in 43% of previously treated NSCLC patients with KRAS G12C mutations.

Updated Pfizer-BioNTech and Moderna bivalent boosters contain spike proteins from the original and BA.4 and BA.5 omicron variants.

Nearly a quarter of patients treated with the peptide-drug conjugate experienced partial remission.

Elahere, a new antibody-drug conjugate, shrank tumors in about a third of treatment-experienced patients.

The topical cream Opzulera (ruxolitinib) can improv skin repigmentation in people with melanoma-associated vitiligo.